Evaluation of regorafenib in colorectal cancer and GIST

This publication has 14 references indexed in Scilit:

• Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
  Published by Elsevier ,2012
• Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
  The Lancet, 2012
• Comprehensive molecular characterization of human colon and rectal cancer
  Nature, 2012
• Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
  British Journal of Cancer, 2012
• Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
  International Journal of Cancer, 2010
• Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
  Journal of Clinical Oncology, 2010
• Colorectal cancer
  The Lancet, 2010
• Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
  Journal of Clinical Oncology, 2008
• Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
  The Lancet, 2004
• Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
  Journal of Clinical Oncology, 2003